Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NM107 (2'-C-Methylcytidine) 是一种具有广谱抗病毒活性的核糖核苷,是丙型肝炎病毒 NS5B 聚合酶的核苷抑制剂,在野生型复制子细胞中的 EC50 为 1.85 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 297 | 现货 | ||
5 mg | ¥ 481 | 现货 | ||
10 mg | ¥ 726 | 现货 | ||
25 mg | ¥ 1,080 | 现货 | ||
50 mg | ¥ 1,280 | 现货 | ||
100 mg | ¥ 2,090 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 496 | 现货 |
产品描述 | NM107 (2'-C-Methylcytidine) is a ribonucleoside with broad-spectrum antiviral activity, is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, NM 107 in the wild-type replicon cells with the EC50 of 1.85 μM |
体外活性 | NM107 reduces the number of viral plaques in BHK-21 cells infected with dengue type 2, reovirus type 1, West Nile, and yellow fever RNA viruses with EC50 values of 95, 26, 80, and 75 μM, respectively. NM107 inhibits hepatitis C virus (HCV) replication (EC50 = 2.2 μM in a replicon assay) and protects MDBK cells from infection with bovine virus diarrhea virus (BVDV; EC50 = 2.2 μM) and human corona virus (HCoV; EC50 = 90 μM). It also reduces infectious virus yield in BHK-21 cells infected with foot-and-mouth disease virus (FMDV; EC50 = 6.4 μM) and swine vesicular disease virus (SVDV; EC50 = 45.2 μM)[1]. |
体内活性 | Prolonged norovirus shedding may occur in certain patients, such as organ transplant recipients. Established a mouse model for persistent norovirus infection (using the mouse norovirus MNV.CR6 strain). The nucleoside viral polymerase inhibitor 2′-C-methylcytidine (2CMC), but not favipiravir (T-705), reduced viral shedding to undetectable levels. Viral rebound was observed after stopping treatment, which was again effectively controlled by treatment with 2CMC. No drug-resistant variants emerged[2]. |
动物实验 | For all experiments, age- and sex-matched mice 8 to 12 weeks of age were infected by oral gavage with 10^6 CCID50 (50% cell culture infective doses) of CR6. At 7 days postinfection (p.i.), mice were left untreated (n = 9) or were treated with 100 mg/kg daily of 2'-C-Methylcytidine(2CMC) subcutaneously for 5 (n = 4), 7 (n = 4), or 11 (n = 4) days. Two more rounds of a 14-day treatment (with an ~4-week interval in between) with 2CMC (n = 10) or favipiravir (200 mg/kg daily by oral gavage [n = 5]) were given. On each day after infection, the general condition and weight of treated and untreated mice were assessed, individual stool samples were collected (whenever possible during one daily period of observation), and levels of MNV RNA were quantified by reverse transcriptase quantitative PCR (RT-qPCR)[2]. |
别名 | NM-107, 2'-C-甲基胞嘧啶核苷, 2'-C-Methylcytidine |
分子量 | 257.24 |
分子式 | C10H15N3O5 |
CAS No. | 20724-73-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (194.37 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 3.8874 mL | 19.4371 mL | 38.8742 mL | 97.1855 mL |
5 mM | 0.7775 mL | 3.8874 mL | 7.7748 mL | 19.4371 mL | |
10 mM | 0.3887 mL | 1.9437 mL | 3.8874 mL | 9.7186 mL | |
20 mM | 0.1944 mL | 0.9719 mL | 1.9437 mL | 4.8593 mL | |
50 mM | 0.0777 mL | 0.3887 mL | 0.7775 mL | 1.9437 mL | |
100 mM | 0.0389 mL | 0.1944 mL | 0.3887 mL | 0.9719 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NM107 20724-73-6 Microbiology/Virology Proteases/Proteasome HCV Protease inhibit NM-107 Inhibitor HCV NM 107 2'-C-甲基胞嘧啶核苷 2'-C-Methylcytidine Hepatitis C virus inhibitor